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Abstract
Background: Associations between mitochondrial genetic abnormalities (variations and copy number, i.e.
mtDNAcn, change) and elevated ROS have been reported in cancer compared to normal cells. Since excessive
levels of ROS can trigger apoptosis, treating cancer cells with ROS-stimulating agents may enhance their death. This
study aimed to investigate the link between baseline ROS levels and mitochondrial genetic abnormalities, and how
mtDNA abnormalities might be used to predict cancer cells’ response to ROS-stimulating therapy.
Methods: Intracellular and mitochondrial specific-ROS levels were measured using the DCFDA and MitoSOX probes,
respectively, in four cancer and one non-cancerous cell lines. Cells were treated with ROS-stimulating agents
(cisplatin and dequalinium) and the IC50s were determined using the MTS assay. Sanger sequencing and qPCR
were conducted to screen the complete mitochondrial genome for variations and to relatively quantify mtDNAcn,
respectively. Non-synonymous variations were subjected to 3-dimensional (3D) protein structural mapping and
analysis.
Results: Our data revealed novel significant associations between the total number of variations in the
mitochondrial respiratory chain (MRC) complex I and III genes, mtDNAcn, ROS levels, and ROS-associated drug
response. Furthermore, functional variations in complexes I/III correlated significantly and positively with mtDNAcn,
ROS levels and drug resistance, indicating they might mechanistically influence these parameters in cancer cells.
Conclusions: Our findings suggest that mtDNAcn and complexes I/III functional variations have the potential to be
efficient biomarkers to predict ROS-stimulating therapy efficacy in the future.
Keywords: Mitochondrial DNA, MtDNA variations, MtDNA copy number, Reactive oxygen species, Cisplatin,
Dequalinium chloride hydrate, ROS-stimulating therapy, Cancer biomarker
Background
Hallmarks of cancer include genome instability and alter-
ations in metabolism, for the latter of which mitochondria
are key regulators [1, 2]. Mitochondria are semiautono-
mous eukaryotic organelles that are considered as cellular
energy powerhouses. They consist of thousands of proteins,
mainly encoded by the nuclear genome, but also 13
encoded by their own genome [3, 4]. Mitochondrial DNA
(mtDNA) is a small circular DNA of 16,569 bp, which
codes for 2 rRNAs (12S and 16S), 22 tRNAs, and protein
subunits for four of the five complexes of the oxidative
phosphorylation system (OXPHOS), namely seven subunits
of NADH dehydrogenase (complex I), one of cytochrome c
reductase (complex III), three of cytochrome c oxidase
(complex IV) and two of ATP synthase (complex V). The
four subunits of respiratory enzyme complex II are totally
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encoded by nuclear DNA (nDNA), and are transcribed and
translated in the cytoplasm and then transported into the
mitochondria [5]. The displacement-loop region (D-loop) is
a long noncoding region of mtDNA approximately 1.1 kbp
long and contains regulatory sequences for replication and
transcription. A number of proteins are implicated in the
replication and transcription of mtDNA, and mitochondrial
transcriptional factor A (TFAM) plays dual roles in these
biological processes through its binding to D-loop [5]. The
number of mitochondria that exist in a human cell ranges
from hundreds to thousands, and each mitochondrion
contains 2–10 mtDNA copies [6]. The synthesis and deg-
radation of mtDNA is rapid and independent of the cell
cycle so the dynamic equilibrium between the two
processes determines the mitochondrial DNA copy number
(mtDNAcn) (reviewed in Ref. [7]). MtDNAcn is strictly
regulated during differentiation, and normal healthy cells
with a high demand for ATP generation via OXPHOS
have higher mtDNAcn than cells with a low ATP require-
ment [8].
The OXPHOS system is implicated in many cellular
processes such as cell communication, differentiation
and apoptosis. Consequently, OXPHOS dysfunction
can lead to the development of several human dis-
eases, including cancers [9]. For example, mutations
in nuclear genes that encode the succinate dehydro-
genase (SDH, MRC complex II) subunits can alter
corresponding subunit structure and consequently
affect MRC complex II activity, substrate levels, react-
ive oxygen species (ROS) production and cell redox
state, which in turn activates oncogenic transcription
factors to regulate expression of target genes and
stimulate cancer cell proliferation [10, 11].
To date, mitochondrial dysfunction and various
mtDNA alterations including point mutations, deletions
and copy number changes have been observed in several
human cancers such as breast, colon, stomach, kidney,
thyroid, head and neck and ovarian cancers [12–14], and
some linked with clinical parameters [15].
A total of 635 mutations have been reported in the D-
loop region, including 510 point mutations, 56 deletions
and 69 insertions. Additional mutations have been iden-
tified in the coding regions: 593 mutations in the com-
plex I subunits, 343 mutations in the complex III, IV
and V subunits, and 165 mutations in the tRNA and
rRNA genes [16]. An increased mtDNAcn has been ob-
served in endometrial [17], untreated head and neck
[18], prostate [18], pancreatic [19] and colorectal [20]
cancers compared to normal cells. On the contrary, a
decrease of mtDNAcn has been associated with renal
[21], thyroid [22], breast [23], previously treated head
and neck [14], hepatic [24] and ovarian cancers com-
pared to normal cells [25]. While mtDNA alterations
such as mutations and changes in mtDNAcn are
commonplace in cancers compared to normal cells,
much more needs to be learnt about how they inter-
relate with each other and how they associate with
underlying biological processes, including ROS produc-
tion and ROS-mediated drug response.
Mitochondria are considered a primary intracellular
site of ROS generation via OXPHOS during ATP gener-
ation [26]. ROS play important roles in cell signalling
pathways such as growth, differentiation, metabolism
and apoptotic cell death signalling (reviewed in Ref.
[27]). ROS have been purported to have a double-edged-
sword effect in cancer cells since low levels of ROS can
play a critical role in promoting cell proliferation and in-
vasion, whereas excessive levels of ROS can cause oxida-
tive damage to intracellular bio-macromolecules and
consequently induce cell death (reviewed in Ref. [28]).
This makes cancer cells vulnerable to agents that further
increase ROS levels, e.g. cisplatin (CDDP) that has been
reported to cause excessive accumulation of ROS result-
ing in cytotoxic effect in various types of cancer such as
ovarian cancer [29], breast cancer [30] and prostate can-
cer [31, 32]. The mitochondria-targeting compound,
dequalinium chloride (DQA), has also been reported to
demonstrate potent anticancer activity in vitro and
in vivo in different malignancies due to the resulting
damage to mtDNA and the inhibition of mitochondrial
complex I rendering elevated ROS generation [33–35].
DQA belongs to a group of chemical agents knows as
delocalised lipophilic cations (DLCs). Positively charged
DLCs are drawn into mitochondria in response to the
negative electric potential across the mitochondrial
membrane. More importantly, the difference in mito-
chondrial transmembrane potential between normal and
cancer cells can cause a ten-fold increase in DLC accu-
mulation in cancer cells compared to their normal coun-
terparts (reviewed in Ref. [36]), making the targeted
mitochondrial accumulation of DLCs an attractive ap-
proach to cancer-specific therapy. Our previous study
confirmed observations by other groups that DLCs such
as DQA preferentially target mitochondria in cancer
cells [37]. Furthermore, DQA may afford enhanced drug
efficacy with reduced side effects due to its cancer-
specific targeting property compared to non-cancer-
specific / nucleus-targeting compounds such as CDDP,
even though both DQA and CDDP induce ROS produc-
tion [37].
The main objectives of our ongoing research are to
prove the therapeutic potential of targeting mitochon-
dria via DLCs in treating cancer and to identify effective
biomarkers (such as ROS and specific mtDNA varia-
tions) that can predict drug response. Our previous
study revealed a positive correlation between baseline
intracellular ROS levels and drug response in human
cancer cell lines. Therefore, baseline ROS levels have
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been proposed as a novel biomarker to predict drug sen-
sitivity [37]. However, since measuring ROS in tissues is
technically challenging, a more straightforward, e.g. gen-
etic, biomarker to indicate the response to ROS-
stimulating agents was sought.
Due to the complexity of the pathways for cancer
development and resistance, which involves the func-
tional cross-talk of mtDNA genes and their related
nuclear genes, it is challenging to prove direct links
between mtDNA variations and phenotype, one rea-
son being the absence of routine laboratory methods
for the genetic manipulation of mammalian mtDNA.
However, one way of proving a link is to demon-
strate a corresponding mitochondrial/cellular effect
in cells/tissues that contain the mtDNA variation.
However, more than one nuclear or mitochondrial
variation may be present, potentially confounding
the interpretation. Recently, we have demonstrated
that 3D structural analysis of mitochondrial proteins
in silico can complement the former approach re-
vealing detailed mechanistic insights into the func-
tional role of variations within mtDNA encoded-
OXPHOS genes [10].
Consequently, the present study aimed to explore the
interrelationship between various mitochondrial genetic
abnormalities (mtDNA variations and mtDNAcn
change), baseline intracellular ROS levels and sensitivity
to ROS-stimulating drugs such as CDDP and DQA
within the same panel of cell lines employed in our pre-
vious study [37]. Here we show that mtDNAcn and the
total number of non-synonymous variations within the
mitochondrial genome have a strong correlation with
both baseline ROS level and drug resistance. 3D struc-
tural modelling of these reveals a subset of variations
that could be responsible for the observed mtDNA
genotype-mitochondrial/cellular phenotype links. While
repeating these experiments with the different mtDNAs
on a standardised nuclear genetic background is war-
ranted, we propose that this is a useful first step in the
characterisation of the cancer cell lines, and reveals a
subset of variations that have the potential to be used to
stratify patient into subgroups that are most likely to
benefit from ROS-stimulating agents in the future.
Methods
Cell culture, drug treatment, and functional assays
Four cancerous (Ishikawa/endometrium, MDA-MB-231/
breast, Caco-2/colon, PC-3/prostate) and one non-
cancerous (PNT-2/prostate) cell lines, two ROS-
stimulating drugs (cisplatin (CDDP) and dequalinium
chloride hydrate (DQA)), the MTS assay to determine
cell viability and IC50s, and the DCFDA and MitoSOX
probes detected with a microplate reader to measure
baseline intracellular ROS and mitochondrial superoxide
levels of cells, respectively, were employed in the study.
Full methodological details of how these procedures
were undertaken have been previously described [37].
All cell lines employed in the study were originally pur-
chased from either the European Collection of Authenti-
cated Cell Cultures/ECACC (Ishikawa, MDA-MB-231,
Caco-2, PNT-2) or the American Type Culture Collec-
tion/ATCC (PC-3).
DNA extraction and measurement of mtDNA copy
number by SYBR Green real-time PCR
DNA extraction and mtDNA copy number measure-
ment were also carried out as previously described [37].
Mitochondrial DNA sequencing and database mining
To assess the mtDNA variations of the cell lines in this
study seventeen primer pairs were designed using
Primer-BLAST (https://www.ncbi.nlm.nih.gov/tools/
primer-blast/index.cgi) to amplify the entire mitochon-
drial genome in overlapping fragments of ~ 1.1 kb (Pri-
mer sequences, location, and expected PCR amplicon
sizes are listed in Table S5).
All PCR amplifications were performed in a 50-μl re-
action containing 1 × PCR buffer, 1.5 mM MgCl2, 0.2
mM dNTPs, 0.2 μM of each forward and reverse primer,
1.25 U GoTaq® G2 Hot Start Polymerase (Promega,
Southampton, UK) and 200 ng of DNA. The amplifica-
tion procedure entailed 95 °C for 15 min, followed by 35
cycles of 95 °C for 40 s, 60 °C for 40 s and 72 °C for 2
min with a final elongation step for 10 min at 72 °C. PCR
products were visualised by gel electrophoresis using
1.2% agarose gel at 125 V for 50 min.
Sanger sequencing, with a read length of 900-1000 bp,
of the PCR products was performed using forward and
reverse primers by Eurofins Genomics (Ebersberg,
Germany), yielding a 2-fold coverage and whole mito-
chondrial genomes in each case. Variations in the mito-
chondrial genome were identified by comparing the
obtained sequences with the NCBI Human Mitochon-
drial Reference Sequence (NC_012920.1; https://www.
ncbi.nlm.nih.gov/nuccore/251831106/) using the Nu-
cleotide BLAST software (https://blast.ncbi.nlm.nih.gov/
Blast.cgi). Identified mtDNA variations were annotated
and their disease association was analysed using online
tools and databases including MitoWheel (http://
mitowheel.org/mitowheel.htmL), MitoMAP (https://
www.mitomap.org/MITOMAP) and Human Mitochon-
drial DataBase (HmtDB; https://www.hmtdb.uniba.it/).
The HmtDB, mtDB (http://www.mtdb.igp.uu.se/) and
MitoMAP were also used to determine the frequencies
of functional mtDNA variations and 310InsC in the D-
loop region in the healthy tissues.
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In silico three-dimensional protein structure mapping and
analysis of variations
A three-dimensional (3D) protein structure mapping
and analysis approach (developed and validated by Lloyd
and McGeehan) [38–40] was used to predict the func-
tional impact of all non-synonymous identified in
mtDNA protein coding regions.
Briefly, the human mtDNA-encoded protein sequences
were used to identify the most homologous OXPHOS
complexes I, III, IV and V available from the RCSB PDB
(Research Collaboratory for Structural Bioinformatics
Protein Data Bank; http://www.rcsb.org/). Then, the best
quality, latest and most similar complex structures were
choosen; complex I – [PDB:5XTD] (Homo sapiens) [41];
complex III – [PDB:5XTE] (Homo sapiens) [41]; com-
plex IV [PDB:5Z62] (Homo sapiens) [42] and complex V
[PDB:5ARA] (Bos taurus) [43].
The atomic co-ordinates of each complex were down-
loaded from the PDB and opened using PyMol (the
PyMOL Molecular Graphics System/Version 1.8; distrib-
uted by Schrödinger, LLC, NY, USA). All identified non-
synonymous variation sites were mapped to their amino
acid locations on the protein structures using PyMol.
COOT software (Crystallographic Object-Oriented
Toolkit) was also used to create PDB files containing all
non-synonymous variations identified. PDB files includ-
ing the variations (created by COOT) were also opened
with PyMol, and compared with the wild-type structures.
Protein structures were displayed in a cartoon style, and
each variation was identified and displayed in the stick
and sphere format.
Detailed analysis of the potential effect of each vari-
ation on protein structure was performed by examining
the type of amino acid change, as well as its location
within the protein. Factors taken into consideration in-
cluded: proximity to important catalytic regions, such as
active sites, binding pockets and subunit interfaces.
Statistical analysis
All data are expressed as mean ± SEM obtained from a
minimum of three independent experiments. Statistical
analyses and graphical representations were produced
using the GraphPad Prism 8.0 program (Graphpad Soft-
ware, CA, USA). More specific descriptions of the statis-
tical tests used to analyse individual data sets are
provided in the associated figure legends. Differences be-
tween groups were considered statistically significant
based on the following criteria: *p < 0.05, **p < 0.01,
***p < 0.001 and ****p < 0.0001.
Potential linear correlation between two variables was
assessed by the Pearson correlation coefficient method
using SPSS (2015) software. Pearson’s r has a value be-
tween + 1 and − 1, where + 1 indicates a total positive
linear correlation, 0 indicates a non-linear correlation,
and − 1 indicates a total negative linear correlation.
Results
Baseline intracellular ROS, mitochondrial superoxide and
drug response levels
Intracellular ROS and mitochondrial superoxide levels
were measured using two fluorescence-labelled probes,
DCFDA and MitoSOX, respectively. Results from those
assays indicated that the cancer cell lines had increased
baseline intracellular ROS and mitochondrial superoxide
levels compared to the non-cancerous cells (PNT-2)
(Fig. 1a & b). Amongst the cancer cell lines, Caco-2 had
the highest baseline intracellular ROS and mitochondrial
superoxide levels whereas Ishikawa had the lowest. Drug
sensitivity levels towards CDDP and DQA were
evaluated for all cell lines by calculating their IC50s.
Data in Fig. 1c & d show that the non-cancerous PNT-2
cells were more sensitive to both drugs compared to the
cancer cells with Caco-2 being the most resistant
whereas Ishikawa the most sensitive amongst the cancer
cells, although in terms of the DQA treatment, PNT-2
was not significantly more sensitive compared to Ishi-
kawa (Fig. 1a).
Mitochondrial genetic profiles
Relative quantification of mtDNAcn was performed
using the SYBR Green PCR technique. The results
showed that cancer cell lines also had increased
mtDNAcn compared to the non-cancerous cells.
Amongst the cancer cell lines, Caco-2 had the highest
baseline mtDNAcn whereas Ishikawa had the lowest
(Fig. 2a). The complete mitochondrial genome of each
cell line was PCR amplified via 17 overlapping amplicons
and the PCR products were confirmed by agarose gel
electrophoresis (a representative gel image is shown in
Figure S1). Sequencing data revealed that the total num-
ber of mtDNA variations in each cancer cell line was
comparable (30, 25, 26 and 36 variations in Ishikawa,
MDA-MB-231, PC-3 and Caco-2, respectively). How-
ever, these numbers were significantly higher than that
in the non-cancerous cell line (PNT-2), in which only 9
variations were identified (Fig. 2b).
Variations within the D-loop region were identified
and Ishikawa, PC-3 and Caco-2 showed greater numbers
of variations in this region compared to PNT-2 and
MDA-MB-231 (Fig. 2c). The sequencing data revealed
that the D-loop region was a hotspot for variations iden-
tified in the present study. Numerous common varia-
tions amongst the cancer cell lines were observed in the
D-loop region (summarised in Table S1). Our results in-
dicated that A73G was detected in Ishikawa, PC-3 and
Caco-2; T195C was identified only in MDA-MB-231 and
PC-3; A263G was a common variation in all the cancer
Zaidieh et al. BMC Cancer          (2021) 21:427 Page 4 of 18
cell lines; 310InsC was observed only in Ishikawa, PC-3
and MDA-MB-231; T16172C was detected in Ishikawa
and PC-3; C16261T occurred in Ishikawa and Caco-2.
None of the common variations seen in the cancer
cells was detected in the non-cancerous cell line
(PNT-2). On the other hand, each cell line harboured
a number of unique variations in the D-loop region
(listed in Table S2). 513InsCA, G16319A, T16325C
and T16519C were found only in the PNT-2 cells;
C150T, C338T, C16223T, C16257A, T16304C and
A16497G were found only in Ishikawa; A153G was
found only in MDA-MB-231; T195C, C16192T,
C16256T, C16270T, C16320T and A16399G were
found only in PC-3; G47A, G185A, G228A, C295T,
C462T, T489C, C16069T and T16126C were found
only in Caco-2.
Progressive increases in the number of non-
synonymous point variations in the protein coding re-
gions (2, 4, 5, 6, 11) were observed in PNT-2, Ishikawa,
MDA-MB-231, PC-3 and Caco-2, respectively (Fig. 2d).
The same trend was observed for non-synonymous point
variations in complexes I and III (1, 3, 4, 5 and 9 varia-
tions) (Fig. 2e), but not complexes IV and V (Fig. 2f).
Numerous common non-synonymous variations among
the cell lines were observed within the mitochondrial
genome (Table S1). Our results indicated that the
A8860G variation was detected in all the cell lines
whereas C14766T was detected only in the cancer cells.
G13708A was identified only in the PC-3 and Caco-2
cells, whereas A15326G was a common variation in the
PNT-2, Ishikawa, MDA-MB-231 and Caco-2 cells. On
the contrary, greater numbers of unique non-
synonymous variations, mainly in complexes I and III,
were observed in the cancer cells (Table S2). The
T3394C point variation was found only in the Ishikawa
cells; C12084T and A13966G were found only in the
MDA-MB-231 cells; T11120C, C13802T and A14793G
were found only in the PC-3 cells. Caco-2 had the high-
est number of unique variations including T4216C,
G7977C, A10398G, A13681G, T14798C, A14927G and
C15452A. No unique variations within complexes I and
III were found in the non-cancerous cells (PNT-2).
Positive correlations between cellular and genetic
parameters
In order to investigate how mitochondrial genetic abnor-
malities might affect the baseline ROS level and drug re-
sponse in the cancer cells, linear regression was
Fig. 1 Intracellular ROS (a) and mitochondrial superoxide (b) levels of the PNT-2, Ishikawa, MDA-MB-231, PC-3 and Caco-2 cell lines are
represented by the fluorescence intensity of DCFDA and MitoSOX respectively. Comparison of the CDDP IC50s and the DQA IC50s amongst the 5
cell lines. The columns represent the CDDP IC50s (c) and the DQA IC50s (d) in the all cell lines. Data are mean ± SEM (N = 3 separate
experiments); p values were calculated using one-way ANOVA with Tukey multiple comparison post-hoc analysis; ns, not significant, *p < 0.05,
**p < 0.01, ***p < 0.001 and ****p < 0.0001
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Fig. 2 Mitochondrial genetic profiles for PNT-2, Ishikawa, MDA-MB-231, PC-3 and Caco-2. a Relative content of mtDNA in the all cell lines
normalised against the house keeping gene (β-actin). The columns represent the relative mtDNAcn of the cell lines. Data are mean ± SEM (N = 3
separate experiments); p values were calculated using one-way ANOVA with Tukey multiple comparison post-hoc analysis; ns, not significant,
*p < 0.05 and ***p < 0.001. b Numbers of the total variations observed in the cell lines. c Numbers of variations identified in the D-loop region in
the cell lines. d Numbers of non-synonymous variations observed in the whole mtDNA protein coding regions. e Numbers of non-synonymous
variations observed in mtDNA coding regions for the complex I and III subunits. f Numbers of non-synonymous variations observed in mtDNA
coding regions for the complex IV and V subunits
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employed to model the relationship between the redox
statuses and CDDP/DQA IC50s. The relationship be-
tween these cellular parameters and each of the follow-
ing genetic parameters: mtDNAcn, total variations, D-
loop variations, non-synonymous variations, and com-
plexes I/III non-synonymous variations, was also
investigated.
Baseline intracellular ROS levels were positively corre-
lated with the resistance levels to both drugs in the cell
lines (Fig. 3a & b), confirming our previous observations
[37]. Positive correlations between mtDNAcn and intra-
cellular ROS, mitochondrial superoxide (Fig. 3c & d),
and resistance levels to both drugs (Fig. 3e & f) in the
cell lines were also observed between the cell lines.
Data in Fig. 3g & h show that numbers of variations in
the complex I and III coding regions were positively cor-
related with the overall ROS and mitochondrial super-
oxide levels. Those non-synonymous variation numbers
were also positively correlated with the IC50s of both
CDDP and DQA (Fig. 3i & j). Similarly, numbers of
non-synonymous variations identified in the coding re-
gions for all the mitochondrial OXPHOS subunits were
also positively correlated with intracellular ROS, mito-
chondrial superoxide and CDDP/DQA IC50s (data not
shown). Neither the D-loop variations or total number
of variations correlated with ROS levels, drug sensitivity
or mtDNAcn (Fig. S2 & 3). These findings indicate that
the following parameters, mtDNAcn, total non-
synonymous variations and non-synonymous variations
in complexes I/III, could serve as biomarkers for ROS
levels and ROS-stimulating drug resistance.
Eight functional variations identified in complexes I and
III
There were 17 non-synonymous and 20 synonymous
variations identified in complexes I, III, IV and V.
Amongst the complex I variations, 9 were non-
synonymous substitutions, of which 2 were located in
MT-ND1, 1 in MT-ND3, 2 in MT-ND4 and 4 in MT-
ND5. As to the complex III variations, 6 MT-CYB sub-
stitutions were identified in total. For the remaining 2
non-synonymous variations, 1 substitution was found in
complex IV affecting MT-COII and 1 substitution was
identified in the MT-ATP6 subunit of complex V.
The 3D structural analysis revealed that of the 17 non-
synonymous variations identified within the mtDNA
protein-coding regions, 8 were predicted to be func-
tional, all in complex I (A10398G (T114A), T11120C
(F121L), C12084T (S442F), A13681G (T449A), G13708A
(A458T), C13802T (T489M), A13966G (T544A)) and
complex III (T14798C (F18L)). No functional variations
were predicted in complexes IV and V. None of the vari-
ations predicted to be functional were found in the non-
cancerous PNT-2 cells.
All the non-synonymous variations and their structural
modelling predictions are summarised in Table 1.
Figure 4, 5 and 6 depict the structural consequences of
the complex I and III variations predicted to be func-
tional. The A10398G mutation, presents in Caco-2 with
the highest baseline ROS and drug IC50, could cause the
disruption of complex I assembly and stability by affect-
ing the association of MT-ND1 and MT-ND3. The re-
placement of T114 by A114 removes the polar sidechain
property of threonine, which is likely to affect the forma-
tion of hydrogen bonds with the MT-ND1 residue
(D283) and weaken the interaction between the two sub-
units, and consequently affect the assembly of the two
subunits and the stability of complex I (Fig. 4). Similarly,
the A13681G, C13802T and A13966G variations,
present in Caco-2, PC-3 and MDA-MB-231 respectively,
cause the disruption of MT-ND5 subunit stability due to
the loss of the hydrogen bonds formed between the resi-
dues within the subunit. Consequently, these variations
are all predicted to weaken the interaction within the
subunit, hence affect the stability of complex I.
The C12084T mutation, presents in MD-MB-231, re-
sults in the disruption of MT-ND4 stability. This vari-
ation replaces serine with phenylalanine (a larger amino
acid) at position 442 (S442F) which is unlikely to be ac-
commodated within the structure. Apart from being of a
larger size, this phenylalanine at position 442 may dis-
rupt and repel another phenylalanine nearby within the
MT-ND4 subunit (i.e. F438) and consequently affect the
stability of complex I (Fig. 5). Similarly, the T11120C
variation in PC-3 and G13708A variation in PC-3 and
Caco-2 cause the disruption of the MT-ND4 and MT-
ND5 subunits respectively due to the lack of accommo-
dation capacity for the newly formed residues. These
intra-subunit disruptions could interfere with the stabil-
isation of the MT-ND4 and MT-ND5 subunits and con-
sequently affect the stability of complex I.
Complex III is at the centre of the OXPHOS system
and the MT-CYB subunit lies at the centre of dimeric
complex III containing two haems and two inhibitor
binding sites, the Qo and Qi sites. T14798C in Caco-2
that results in the amino acid change F18L is located at
the ubiquinone-binding site (i.e. the Qi site) of the MT-
CYB subunit. Phenylalanine (F) is one of the residues
that form the entrance of the Qi site of complex III [44].
Both phenylalanine (F) and leucine (L) are hydrophobic.
However, they differ in their side chains. Leucine does
not have an aromatic side chain, which makes it smaller
than phenylalanine. Therefore, this substitution is likely
to alter the shape and size of the Qi site because it re-
sults in a larger cavity at the entrance to the site (Fig. 6).
Such a change may interfere with the binding and dis-
sociation of ubiquinone, the Qi site ligand, and conse-
quently the electron transfer from heme bH.
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Fig. 3 (See legend on next page.)
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On the contrary, nine variations were predicted to be
non-functional. These were: T3394C (Y30H) and
T4216C (Y304H) in complex I; C14766T (T7I),
A14793G (H16R), A14927G (T61A), A15326G (T194A)
and C15452A (L236I) in complex III; G7977C (G131A)
in complex IV; A8860G (T112A) in complex V. The
structural analysis revealed that all those residues were
distal from any known electron or proton route or major
catalytic sites, and did not have any direct interaction
with amino acids from neighbouring mitochondrial or
nuclear subunits. There also appeared to be sufficient
room to accommodate the amino acid change in each
case.
The combined effect of individual non-synonymous
variations predicted to be functional in our study by 3D
structural modelling is expected to be magnified if more
than one is present in a cell/cell line, and so it is note-
worthy that there was a positive correlation between the
number of non-synonymous variations in complexes I
and III predicted to be functional with the overall ROS
and mitochondrial superoxide levels, and CDDP/DQA
IC50s (Fig. 7). This finding suggests that an increasing
number of non-synonymous variations predicted to have
an effect on the structure and function of complexes I
and III could provide a mechanistic link to the other
effects observed, i.e. associated increase in ROS, drug
resistance and mtDNAcn.
This can also be illustrated by comparing the cancer-
ous PC-3 and non-cancerous PNT-2 cell lines, both of
which originated from prostate tissue. Clearly, all the pa-
rameters, including baseline intracellular ROS and mito-
chondrial superoxide levels, CDDP and DQA resistance,
mtDNA copy number, total number of variations, total
number of D-loop variations, total number of non-
synonymous point mutations in protein coding regions
and in complexes I and III, are elevated in PC-3 com-
pared to PNT-2. Furthermore, it is worth noticing that
the PC-3 cells contains three variations predicted to be
functional (C13802T, G13708A, and T11120C), whereas
the PNT-2 cells do not contain any.
Varying frequency in healthy tissues and heritability of
functional variations
Among the subset of 8 variations classified as functional,
only three: A10398G, G13708A and T14798C occur fre-
quently in healthy tissues, i.e. more than 500 in 30,000
(1.6%) of complete mitochondrial genomes in at least 2
out 3 of the consulted databases (Table S3). On the
other hand, 5 of the functional variations: A13966G,
T11120C, C12084T, A13681G and C13802T as well as
the D-loop variation 310InsC occur rarely in healthy tis-
sues, i.e. less than 1.6% of the complete mitochondrial
genomes in at least 2 out of 3 of the databases consulted
(Table S3). A MitoMAP search of the subset of the 8
functional variations and 310IncC revealed that 5 have
not been previously reported as either somatic or inher-
ited variations, i.e. they are of unknown heritability
(T11120C, C12084T, A13681G, C13802T, and 310InsC);
three have been reported as somatic or inherited
(A10398G, G13708A and T14798C), and one has been
reported as inherited (A13966G) (Table S3). While our
results indicate that variations occurring at low frequen-
cies in healthy tissues are more likely to be previously
unreported variations of potential functional importance,
the possibility that previously reported somatic or inher-
ited variations occurring at high frequencies in healthy
tissues could also play a role in increased baseline ROS
level, drug resistance and mtDNAcn cannot be ruled
out.
Discussion
It has become broadly acknowledged that the redox sta-
tus of cancer cells could be manipulated to achieve
cancer-specific killing since high levels of intracellular
ROS activate death signal pathways (reviewed in Ref.
[27]). Given that mitochondria are a primary intracellu-
lar site of ROS production via OXPHOS during ATP
generation [26], it is not surprising that mitochondria
have attracted increasing research interest as a promis-
ing target for anticancer therapy. It has been reported
that mtDNA mutations could influence intracellular
ROS levels [45, 46]. In particular, since complexes I and
III are the main ROS generation sites, variations in their
mtDNA genes could have a significant impact on the
overall intracellular ROS level (reviewed in Ref. [47]).
However, how specific mtDNA variations influence the
efficacy of mitochondria-targeting/ROS-stimulating ther-
apy remains unclear. Our previous data have shown that
elevated baseline intracellular ROS levels among differ-
ent cancer cell lines correlate positively with increased
resistance towards cisplatin and dequalinium, both being
ROS-stimulating drugs [37]. We hypothesised that cer-
tain mitochondrial genetic abnormalities, including vari-
ations and copy number (mtDNAcn) changes, could
(See figure on previous page.)
Fig. 3 Positive correlation between the baseline intracellular ROS level and drug resistance against CDDP (a) and DQA (b). Positive correlations
between the relative content of mtDNA and the baseline intracellular ROS level (c), mitochondrial superoxide level (d), CDDP IC50s (e), DQA IC50s
(f). Positive correlations between the numbers of non-synonymous variations in the complexes I & III coding regions and baseline ROS levels (g),
mitochondrial superoxide levels (h), CDDP IC50s (i), DQA IC50s (j). Data points representing the cell lines are in the sequence of PNT-2, Ishikawa,
MDA-MB-231, PC-3 and Caco-2. r and p and values were calculated using the Pearson correlation coefficient method; *p < 0.05 and **p < 0.01
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influence intracellular ROS levels, and therefore be uti-
lised as biomarkers to predict cancer cells’ response to
ROS-stimulating agents. The present study characterised
the interrelationship between mitochondrial genetic pa-
rameters (variation and mtDNAcn), ROS levels and
ROS-mediated drug response with the aim of generating
future novel biomarkers that have a significant associ-
ation with drug response of cancer cells. Such bio-
markers have the potential to be integrated into future
clinical practice in order to facilitate personalised
medicine.
As a first step to investigating the possible link be-
tween mitochondrial genetic abnormalities and the cells’
response to ROS-stimulating agents, a range of molecu-
lar, biochemical and bioinformatics methods were
employed in the present study to analyse ROS levels,
cytotoxicity of cisplatin and dequalinium, as well as
mtDNA variations and relative copy numbers in 4 can-
cer and 1 non-cancerous cell lines (two of the cell lines,
cancerous PC-3 and non-cancerous PNT-2, originated
from the same tissue type, i.e. prostate).
We found that cancer cells generally carry more varia-
tions and a higher mtDNAcn in their mitochondrial gen-
ome than non-cancerous cells and have higher baseline
ROS levels. This is consistent with the observations of
others [47–49] and likely reflects the cancer cells’ adap-
tion to oxidative stress via enhanced DNA repair mecha-
nisms, upregulated anti-apoptotic pathways and
consequently increased drug resistance/cell survival
(reviewed in Ref. [28]).
We also confirmed our previous observation that in-
creasing baseline ROS level correlates positively with in-
creasing resistance to the ROS-stimulating agents in
cancer cell lines. We further demonstrated that in-
creased ROS and drug resistance levels also correlate
positively with greater mtDNAcn, higher number of
non-synonymous complex I and III variations, and
higher number of complex I and III functional variations
predicted by the 3D structural modelling (i.e. A10398G,
T11120C, C12084T, A13681G, G13708A, C13802T,
A13966G and T14798C) (Table S4). The positive correl-
ation between the number of predicted complex I/III
Fig. 4 Detailed view of the complex I variation A10398G (T114A). T114 is located at the surface of complex I within the mitochondrial DNA
encoded MT-ND3 subunit. MT-ND3 is shown in purple and MT-ND1, an adjacent subunit, in yellow. The wild type T114 is shown in orange as
sticks and spheres (a & c, respectively) and the mutant A114 is shown in red (b & d). Alanine is non-polar and smaller than threonine in size
meaning the change is likely to result in the loss of hydrogen bonds (dotted line) with the D283 residue of MT-ND1, and therefore affect the
association of the two subunits and consequently the stability of complex I
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functional variations and ROS levels appears more sig-
nificant for mitochondrial ROS than for overall intracel-
lular ROS. Since complexes I and III are the main
contributors to mitochondrial ROS generation, it is not
surprising that cancer cells carrying larger numbers of
functional variations located in these two complexes
would produce higher levels of mitochondrial ROS, as
shown in this study.
Intriguingly, the positive correlation between the num-
ber of predicted complex I/III functional variations and
drug IC50 seems more marked for cisplatin than for
dequalinium. This suggests that cisplatin, a conventional
nDNA-targeting compound, may rely more on elevated
mitochondrial ROS to promote drug resistance in cancer
cells compared to dequalinium, a mitochondria-targeting
compound. Our observation was echoed by a recent
study in which cisplatin-resistant lung cancer cells dem-
onstrated increased mitochondrial mass through upregu-
lation of PGC-1α (the predominant mitochondrial
biogenesis promoter) and consequently enhanced intra-
cellular ROS production upon cisplatin treatment [50].
Our data support the previously proposed theory that
cancer cells may develop resistance towards cisplatin by
upregulating mitochondrial ROS production in order to
stimulate anti-apoptotic pathways and promote cell sur-
vival [50]. We speculate that this mechanism could be
triggered by certain nucleus-mitochondria crosstalk in
response to cisplatin treatment. On the contrary, unlike
cisplatin, dequalinium is a mitochondria-targeting com-
pound and therefore may not initiate such crosstalk, at
least not to the same degree, upon entering the cells.
This may explain the much lower IC50s of dequalinium
observed in the cancer cells compared to the IC50s of
cisplatin in the present study. Furthermore, our data and
the previously published data support our hypothesis
that mitochondria-targeting therapy can be more effect-
ive than conventional therapy since the latter may trig-
ger nucleus-mitochondria crosstalk to promote cell
survival.
Using 3D structural modelling, we predicted 8 func-
tional OXPHOS variations: A10398G, T11120C,
C12084T, A13681G, G13708A, C13802T, and A13966G
are likely to destabilise complex I, impacting on corre-
sponding enzyme activity, which in turn may affect ROS
Fig. 5 Detailed view of the complex I variation C12084T (S442F). S442 is located at the core of complex I within the mitochondrial DNA encoded
MT-ND4 subunit. MT-ND4 is shown in bright green. The wild type S442 is shown in orange sticks and spheres (a & c, respectively) and the mutant
F442 is shown in red (b & d). Phenylalanine is bigger than serine due to its aromatic side chain and is likely to disrupt and repel the hydrophobic
F438 residue within MT-ND4, which is predicted to affect the stability of complex I
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levels and drug response. In support of this view,
A10398G was reported in various types of cancer includ-
ing brain, breast and cervical cancer, and strongly associ-
ated with elevated levels of ROS [51–54]; T11120C and
C13802T was found in the PC3 cells (but not the PNT-2
cells) previously and shown to inhibit OXPHOS and in-
crease ROS production, and consequently promote
tumour growth in vivo when those PC-3 cells were
injected into nude mice [55]; C12084T and A13966G
variations found in the MDA-MB-231 cells were previ-
ously reported to be responsible for reduced complex I
activity and enhanced metastatic potential via ROS over-
production and the resultant overexpression of Hif-1α
[56, 57]. While G13708A in complex I has been reported
in various types of cancer such as breast and colorectal
cancer [58, 59], A13681G has no previously reported
disease associations. There are no previous reports docu-
menting G13708A or A13681G and ROS levels, al-
though our predictions suggest this would be worth
investigating. On the other hand, we predict that the
final functional OXPHOS mutation: T14798C, despite
frequently occurring in the healthy population (like
some of the other variations; Table S3), is likely to affect
the association/dissociation of ubiquinone at the Qi-site,
impacting on the activity of complex III, and this in turn
may affect the levels of ROS produced by the complex
and consequently drug response. In support of this view,
a study conducted by Keatley et al. demonstrated that
glioblastoma cell lines that carried T14798C had ele-
vated complex III activity, oxidative stress, and different
drug sensitivity levels compared to cells that did not
contain the mutation. Further, glioblastoma patients
with T14798C had worse prognosis than non-carriers
[10]. This is in keeping with an earlier study which dem-
onstrated that the activity of yeast mutant complex III
genetically manipulated to contain the equivalent vari-
ation of T14798C was significantly impaired and the
mutant showed more sensitivity to mitochondrial-
targeting compounds [60].
In contrast to increased ROS and drug resistance levels
correlating positively with greater mtDNAcn, larger num-
ber of non-synonymous complex I and III variations, and
Fig. 6 Detailed view of the complex III variation T14798C (F18L). F18 is located at the entrance of the ubiquinone-binding site (Qi site) within the
mitochondrial DNA encoded cytochrome b subunit (MT-CYB). MT-CYB is shown in yellow and ubiquinone in green. The wild type F18 is shown in
purple sticks and spheres (a & c, respectively) and the mutant L18 is shown in red (b & d). Phenylalanine is a much larger residue than leucine,
suggesting that this change is likely to affect the shape and structure of the binding site, the on/off rate of ubiquinone, and consequently alter
the activity of complex III
Zaidieh et al. BMC Cancer          (2021) 21:427 Page 13 of 18
larger number of predicted complex I and III functional
variations, none of these parameters correlated with the
number of D-loop variations. The mtDNAcn result is sur-
prising given that the D-loop region is a major control site
for mtDNA replication and transcription, and higher
mtDNAcn has been reported in various types of cancer
carrying D-loop variations [61, 62]. One possibility is that
specific variations located within the light and heavy
strand promoters in the D-loop region rather than the
total number of D-loop variations are more important.
Such variations could affect the binding affinities of the
initiators and modulators of mtDNA transcription, thus,
disturbing the rate of transcription, RNA primer synthesis
as well as mtDNA replication at the H-strand origin of
replication (OH) [63]. In other words, quality is more im-
portant than quantity in terms of functional variations in
the D-loop region. In the present study, only one variation
appeared to be located in a key regulatory region. Indeed,
310InsC, present in Ishikawa, MDA-MB-231 and PC-3
cells, is located in CSB2, one of the three conserved se-
quence blocks within the H-strand origin of replication
(OH) that harbours critical functional motifs for the initi-
ation and regulation of H-strand replication. Given that
insertion variations have a real fundamental impact on
DNA function, as they completely change the sequence of
the region and result in the shift of the original functional
motifs, it is likely that the 310InsC variation may interfere
with DNA-primer interaction and have a negative impact
on the replication of the H-strand in those cell lines. This
observation might explain why the above cell lines had
lower mtDNA copy numbers compared to Caco-2 that
did not harbour this insertion.
The apparent relationship between mtDNAcn, ROS
levels and drug IC50s could also represent cellular adap-
tation to the level of OXPHOS activity that in turn
might be related to the number of functional OXPHOS
variations. One example of such adaptation includes the
retrograde signalling pathway, where dysfunctional mito-
chondria (caused by functional OXPHOS variations) can
lead to differences in ROS levels, which in turn lead to
the activation of various nuclear responses, consequently
promoting multiple pathways that regulate energy
homeostasis, oxidative stress, mitophagy, fission, fusion
and other functions to facilitate cellular adaption strat-
egies and hence regulate the transcription and transla-
tion of genes responsible for mitochondrial biogenesis
(e.g. PGC-1α), mtDNA replication and OXPHOS func-
tions [64]. Taking these observations together, we
propose that cell line-specific functional OXPHOS vari-
ation profiles could mechanistically contribute to the
mitochondrial activity, baseline ROS levels, mtDNAcn
and response to ROS-stimulating agents observed in
Fig. 7 Positive correlations between the numbers of functional variations predicted in the complex I & III coding regions and baseline ROS levels
(a), mitochondrial superoxide levels (b), CDDP IC50s (c) and DQA IC50s (d). Data points representing the cell lines are in the sequence of PNT-2,
Ishikawa, MDA-MB-231, PC-3 and Caco-2. r and p and values were calculated using the Pearson correlation coefficient method; *p < 0.05
and **p < 0.01
Zaidieh et al. BMC Cancer          (2021) 21:427 Page 14 of 18
cancer (Fig. 8), and the best illustration of this from our
study is the comparison between the cancerous PC-3
cells and non-cancerous PNT-2 cells, as they are both
derived from prostate.
A recent publication by Cocetta and co-authors pro-
vides a sophisticated review on mitochondrial involve-
ment in cisplatin resistance [65]. As pointed out by the
authors, so far, existing knowledge of the retrograde sig-
nalling is still very limited. Based on our data and the
findings from a previous study linking PGC-1α upregula-
tion with increased mitochondrial mass in cisplatin-
resistant lung cancer cells [50], we present a hypothesis
illustrated below in Fig. 8. Our data clearly indicate that
specific functional variations in the OXPHOS complexes
I and III are responsible for enhanced ROS production
and the subsequent retrograde communication, render-
ing resistance to cisplatin. Our data not only support
previous findings that redox imbalance and nucleus-
mitochondria crosstalk play important roles in cisplatin
resistance, but also provide a potential mechanistic link
to specific mtDNA variations. Furthermore, our studies
were not restricted to cisplatin only, hence our findings
would provide insights into the broader area of ROS-
stimulating/mitochondria-targeting therapy as well as
the related biomarker studies.
Measuring mitochondrial activity and the expression
level of genes controlling the mitochondrial biogenesis
and mtDNA replication, such as PGC-1α, DNA poly-
merase γ (POLγ) and mitochondrial transcriptional fac-
tor A (TFAM), in the future would obviously help
corroborate this hypothesis.
Now that we know the characteristics of the cell lines
in detail, there are a number of approaches that could be
employed in the future to further validate our hypothesis
that functional OXPHOS variation or a group of varia-
tions contribute to the intracellular ROS/drug response
phenotypes observed. One way would be to create
cybrids which involves the transfer of the cancer cell
mitochondria/mtDNA containing the functional
OXPHOS variations onto a common wild type nuclear
background, and the observation whether the cellular
phenotype is transferred. However, the process of gener-
ating cybrids is not without its problems and can create
irreversible epigenetic changes [66], as well as nuclear
genome instability and variation [67], potentially con-
founding the ability to identify one single mtDNA vari-
ation (or a group of mtDNA variations) as the
contributing factor(s), and so the insights generated in
this paper, especially the comparison between PC-3 and
PNT-2, are still useful. Another possibility would be to
Fig. 8 Proposed mechanism of functional OXPHOS mutation-mediated cell survival upon treatment with ROS-stimulating agents in cancer cells.
The 3D-structures of OXPHOS complexes I-V with the nuclear-encoded subunits shown as ribbons (grey) and mitochondrial-encoded subunits
shown as space filling model (yellow). Functional OXPHOS variations (red spheres) lead to the overproduction of ROS (blue) and mitochondrial
dysfunction which in turn trigger cellular adaptation mechanisms by activating nuclear responses. In response to oxidative stress, nucleus (light
purple) upregulates the transcription of genes responsible of mitochondrial biogenesis (e.g. PGC-1α, light orange) and mtDNA (open green
circles) replication and transcription in order to compensate the mutated copies of mtDNA and avoid the over accumulation of ROS. The positive
correlations between the total number of functional OXPHOS variations, ROS level, mtDNAcn and drug resistance observed in the present study
indicate that oxidative stress could promote cancer cell survival via nucleus-mitochondria crosstalk
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introduce the functional OXPHOS variations into Sac-
charomyces cerevisiae (Baker’s yeast) cells, as unlike
mammalian mtDNA, its mitochondrial genome is amen-
able to genetic manipulation. This has proved useful for
the functional validation of T14798C [60], but the lack
of respiratory complex I in S. cerevisiae precludes a simi-
lar validation of functional complex I variations identi-
fied in this study. Recent technological advances suggest
that such precise manipulation of mammalian mtDNA
(and thus the functional validation of complex I varia-
tions) may be possible in the future, and may in fact pro-
vide a better alternative for functionally validating
mtDNA variations than both cybrids and the yeast
model system [68].
It is worth mentioning that two cell lines of distinctly
opposite characteristics were identified among the tested
cancer cell lines in our studies that was either the most
sensitive (i.e. Ishikawa) or the most resistant (i.e. Caco-
2) to ROS-stimulating therapy. The profiles of Ishikawa
and Caco-2 based on the ROS/mtDNAcn/functional
complexes I/III mutation parameters could be further
validated as benchmarks to assess cancer cells’ response
towards ROS-stimulating therapy. In addition, these two
cell lines would make for interesting candidates for fu-
ture downstream cybrid/mtDNA gene editing studies to
help validate that the differences observed in the present
study are due to mtDNA pattern and not due to differ-
ences in their nuclear proteomes.
Conclusions
Our data showed significant correlations between mito-
chondrial genetic abnormalities and the baseline ROS
levels and drug resistance in cancer cells. In particular,
we highlight an association between elevated mtDNAcn,
higher frequency of predicted functional non-
synonymous variations in complexes I/III, elevated base-
line ROS levels and enhanced drug resistance (Table S4).
Consequently, screening patients for mtDNAcn and the
key functional variations identified in this study
(A10398G, T11120C, C12084T, A13681G, G13708A,
C13802T, A13966G and T14798C) could provide health-
care professionals with useful information in terms of
predicting a patient’s response to the treatment and de-
signing personalised therapy in the future. It is worth
mentioning that since the mtDNA mutations were iden-
tified using the Sanger sequencing method, we were un-
able to ascertain the level of heteroplasmy of these key
functional variations. However, the fact that those varia-
tions were successfully detected by Sanger sequencing
indicates that they are significantly abundant in the col-
lective mitochondrial genome. Nevertheless, a more ad-
vanced technique such as Next Generation Sequencing
would be able to provide such information in future
studies and allow us to evaluate whether the extent of
heteroplasmy also affects intracellular ROS and the asso-
ciated drug sensitivity. Furthermore, the present study
was carried out on a small number of samples, and we
were unable to test more cell lines (particularly more
paired cancer/non-cancerous cell lines) due to limited
resources. However, our existing data clearly indicate
the potential of the aforementioned mtDNA variations
as biomarkers to predict cancer cells’ response to ROS-
stimulating agents, and therefore warrant further investi-
gations in this direction.
Abbreviations
MRC: Mitochondrial respiratory chain; mtDNA: Mitochondrial DNA;
OXPHOS: Oxidative phosphorylation system; nDNA: Nuclear DNA; D-
loop: Displacement loop; TFAM: Mitochondrial transcriptional factor A;
mtDNAcn: Mitochondrial copy number; SDH: Succinate dehydrogenase;
ROS: Reactive oxygen species; CDDP: Cisplatin; DQA: Dequalinium chloride
hydrate; HmtDB: Human Mitochondrial DataBase; RCSB PDB: Research
Collaboratory for Structural Bioinformatics Protein Data Bank;
COOT: Crystallographic Object-Oriented Toolkit; Qi site: Ubiquinone-binding
site; F: Phenylalanine; L: Leucine; TM: Transmembrane; POLγ: DNA
polymerase γ
Supplementary Information
The online version contains supplementary material available at https://doi.
org/10.1186/s12885-021-08155-2.
Additional file 1: Figure S1. Representative image of agarose gel
electrophoresis of PCR products. Figure S2. Correlation between the D-
loop variations and the baseline intracellular ROS level, mitochondrial
superoxide level, drug resistance against CDDP and DQA, relative content
of mtDNA and the total number of variations. Figure S3. Correlation be-
tween the total variations and the baseline intracellular ROS level, mito-
chondrial superoxide level, drug resistance against CDDP and DQA and
relative content of mtDNA. Table S1. List of common variations identi-
fied in the 5 cell lines. Table S2. List of unique variations identified in
the 5 cell lines. Table S3. Summary of frequency in healthy tissues and
heritability of functional variations identified in the 5 cell lines. Table S4.
Summary of correlations between mtDNA parameters and ROS-
stimulating drug IC50s, intracellular and mitochondrial ROS. Table S5.
List of the primers designed to amplify 17 overlapping mtDNA
fragments.
Acknowledgements
We wish to thank the Council for At-Risk Academics (cara) and the University
of Portsmouth for supporting T.Z.’s PhD study. The authors wish to thank Dr.
Rhiannon McGeehan for her invaluable contributions towards the conceptu-
alisation, training and data analysis/interpretation of the in silico protein
mapping work, as well as her constructive comments and significant input
during the preparation and the revision of the manuscript. The authors also
wish to thank Ms. Louisa Emms for sharing her intellectual discussions
around the topic of mitochondrial complex structures.
Authors’ contributions
Conceptualization, Qian An; Data curation, Tarek Zaidieh; Formal analysis,
Tarek Zaidieh and Qian An; Investigation, Tarek Zaidieh and Qian An;
Methodology, Tarek Zaidieh, James R. Smith, Karen E. Ball and Qian An;
Project administration, Qian An; Resources, Qian An; Supervision, James R.
Smith, Karen E. Ball and Qian An; Writing – original draft, Tarek Zaidieh,
James R. Smith, Karen E. Ball and Qian An; Writing – review & editing, Tarek
Zaidieh, James R. Smith, Karen E. Ball and Qian An. All authors have read and
agreed to the published version of the manuscript.
Zaidieh et al. BMC Cancer          (2021) 21:427 Page 16 of 18
Funding
This work was internally funded by the University of Portsmouth. The
University does not have a role in the design of the study and collection,
analysis, and interpretation of data, nor in writing the manuscript.
Availability of data and materials
Data generated or analysed during this study are included in this article and
its supplementary information document. Sequencing data have been
deposited to the NIH genetic sequence database GenBank and are
accessible via the following accession numbers: MW344639 (PNT-2),
MW344640 (Ishikawa), MW344641 (MD-MBA-231), MW344642 (PC-3),
MW344643 (Caco-2). Other raw data used and/or analysed during the
current study are available from the corresponding author upon reasonable
request.
Declarations
Ethics approval and consent to participate
Not applicable (No human subjects or human tissues were involved in this
study; ethics approval was not required for the use of the commercial cell




The authors declare that they have no competing interests.
Author details
1School of Pharmacy and Biomedical Sciences, Institute of Biological and
Biomedical Sciences, University of Portsmouth, St Michael’s Building, White
Swan Road, Portsmouth PO1 2DT, UK. 2Institute of Life Science, Swansea
University Medical School, Swansea SA2 8PP, UK.
Received: 23 November 2020 Accepted: 6 April 2021
References
1. Keogh MJ, Chinnery PF. Mitochondrial DNA mutations in
neurodegeneration. Biochim Biophys Acta. 2015;1847(11):1401–11. https://
doi.org/10.1016/j.bbabio.2015.05.015.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell.
2011;144(5):646–74. https://doi.org/10.1016/j.cell.2011.02.013.
3. Taanman JW. The mitochondrial genome: structure, transcription, translation
and replication. Biochim Biophys Acta. 1999;1410(2):103–23. https://doi.org/1
0.1016/S0005-2728(98)00161-3.
4. Vafai SB, Mootha VK. Mitochondrial disorders as windows into an ancient
organelle. Nature. 2012;491(7424):374–83. https://doi.org/10.1038/nature11
707.
5. Cormio A, Sanguedolce F, Musicco C, Pesce V, Calò G, Bufo P, et al.
Mitochondrial dysfunctions in bladder cancer: exploring their role as disease
markers and potential therapeutic targets. Crit Rev Oncol Hematol. 2017;
117:67–72. https://doi.org/10.1016/j.critrevonc.2017.07.001.
6. Seyfried TN. Cancer as a mitochondrial metabolic disease. Front Cell Dev
Biol. 2015;3:1–12.
7. Shadel GS, Clayton DA. Mitochondrial DNA maintenance in vertebrates.
Annu Rev Biochem. 1997;66(1):409–35. https://doi.org/10.1146/annurev.
biochem.66.1.409.
8. Lee W, Johnson J, Gough DJ, Donoghue J, Cagnone GL, Vaghjiani V, et al.
Mitochondrial DNA copy number is regulated by DNA methylation and
demethylation of POLGA in stem and cancer cells and their differentiated
progeny. Cell Death Dis. 2015;6(2):e1664. https://doi.org/10.1038/cddis.201
5.34.
9. Mei H, Sun S, Bai Y, Chen Y, Chai R, Li H. Reduced mtDNA copy number
increases the sensitivity of tumor cells to chemotherapeutic drugs. Cell
Death Dis. 2015;6(4):e1710. https://doi.org/10.1038/cddis.2015.78.
10. Keatley K, Stromei-Cleroux S, Wiltshire T, Rajala N, Burton G, Holt WV, et al.
Integrated approach reveals role of mitochondrial germ-line mutation F18L
in respiratory chain, oxidative alterations, drug sensitivity, and patient
prognosis in glioblastoma. Int J Mol Sci. 2019;20(13):3364. https://doi.org/1
0.3390/ijms20133364.
11. Grimm S. Respiratory chain complex II as general sensor for apoptosis.
Biochim Biophys Acta Bioenerg. 1827;2013:565–72.
12. Dang S, Qu Y, Wei J, Shao Y, Yang Q, Ji M, et al. Low copy number of
mitochondrial DNA (mtDNA) predicts worse prognosis in early-stage
laryngeal cancer patients. Diagn Pathol. 2014;9(28):1–9.
13. Park JS, Sharma LK, Li H, Xiang R, Holstein D, Wu J, et al. A heteroplasmic,
not homoplasmic, mitochondrial DNA mutation promotes tumorigenesis
via alteration in reactive oxygen species generation and apoptosis. Hum
Mol Genet. 2009;18(9):1578–89. https://doi.org/10.1093/hmg/ddp069.
14. Jiang WW, Rosenbaum E, Mambo E, Zahurak M, Masayesva B, Carvalho AL,
et al. Decreased mitochondrial DNA content in posttreatment salivary rinses
from head and neck cancer patients. Clin Cancer Res. 2006;12(5):1564–9.
https://doi.org/10.1158/1078-0432.CCR-05-1471.
15. Yuan Y, Ju YS, Kim Y, Li J, Wang Y, Yoon CJ, et al. Comprehensive molecular
characterization of mitochondrial genomes in human cancers. Nat Genet.
2020;52(3):342–52. https://doi.org/10.1038/s41588-019-0557-x.
16. Lu J, Sharma LK, Bai Y. Implications of mitochondrial DNA mutations and
mitochondrial dysfunction in tumorigenesis. Cell Res. 2009;19(7):802–15.
https://doi.org/10.1038/cr.2009.69.
17. Wang Y, Liu VW, Xue WC, Tsang PC, Cheung AN, Ngan HY. The increase of
mitochondrial DNA content in endometrial adenocarcinoma cells: a
quantitative study using laser-captured microdissected tissues. Gynecol
Oncol. 2005;98(1):104–10. https://doi.org/10.1016/j.ygyno.2005.04.015.
18. Jiang WW, Masayesva B, Zahurak M, Carvalho AL, Rosenbaum E, Mambo E,
et al. Increased mitochondrial DNA content in saliva associated with head
and neck cancer. Clin Cancer Res. 2005;11(7):2486–91. https://doi.org/10.11
58/1078-0432.CCR-04-2147.
19. Lynch SM, Weinstein SJ, Virtamo J, Lan Q, Liu CS, Cheng WL, et al.
Mitochondrial DNA copy number and pancreatic cancer in the alpha-
tocopherol beta-carotene cancer prevention study. Cancer Prev Res. 2011;
4(11):1912–9. https://doi.org/10.1158/1940-6207.CAPR-11-0002.
20. Feng S, Xiong L, Ji Z, Cheng W, Yang H. Correlation between increased copy
number of mitochondrial DNA and clinicopathological stage in colorectal
cancer. Oncol Lett. 2011;2(5):899–903. https://doi.org/10.3892/ol.2011.322.
21. Purdue MP, Hofmann JN, Colt JS, Hoxha M, Ruterbusch JJ, Davis FG, et al. A
case-control study of peripheral blood mitochondrial DNA copy number
and risk of renal cell carcinoma. PLoS One. 2012;7(8):e43149. https://doi.
org/10.1371/journal.pone.0043149.
22. Mambo E, Chatterjee A, Xing M, Tallini G, Haugen BR, Yeung SC, et al.
Tumor-specific changes in mtDNA content in human cancer. Int J Cancer.
2005;116(6):920–4. https://doi.org/10.1002/ijc.21110.
23. Bai RK, Chang J, Yeh KT, Lou MA, Lu JF, Tan DJ, et al. Mitochondrial DNA
content varies with pathological characteristics of breast cancer. J Oncol.
2011;2011:496189.
24. Morten KJ, Ashley N, Wijburg F, Hadzic N, Parr J, Jayawant S, et al. Liver
mtDNA content increases during development: a comparison of methods
and the importance of age- and tissue-specific controls for the diagnosis of
mtDNA depletion. Mitochondrion. 2007;7(6):386–95. https://doi.org/10.1016/
j.mito.2007.09.001.
25. Wang Y, Liu VW, Xue WC, Cheung AN, Ngan HY. Association of decreased
mitochondrial DNA content with ovarian cancer progression. Br J Cancer.
2006;95(8):1087–91. https://doi.org/10.1038/sj.bjc.6603377.
26. Vaseghi H, Houshmand M, Jadali Z. Increased levels of mitochondrial DNA
copy number in patients with vitiligo. Clin Exp Dermatol. 2017;42(7):749–54.
https://doi.org/10.1111/ced.13185.
27. Zou Z, Chang H, Li H, Wang S. Induction of reactive oxygen species: an
emerging approach for cancer therapy. Apoptosis. 2017;22(11):1321–35.
https://doi.org/10.1007/s10495-017-1424-9.
28. Georgieva E, Ivanova D, Zhelev Z, Bakalova R, Gulubova M, Aoki I.
Mitochondrial dysfunction and redox imbalance as a diagnostic marker of
"free radical diseases". Anticancer Res. 2017;37(10):5373–81. https://doi.org/1
0.21873/anticanres.11963.
29. Meng Y, Chen CW, Yung MMH, Sun W, Sun J, Li Z, et al. DUOXA1-mediated
ROS production promotes cisplatin resistance by activating ATR-Chk1
pathway in ovarian cancer. Cancer Lett. 2018;428:104–16. https://doi.org/1
0.1016/j.canlet.2018.04.029.
30. Pluchino LA, Choudhary S, Wang HC. Reactive oxygen species-mediated
synergistic and preferential induction of cell death and reduction of
clonogenic resistance in breast cancer cells by combined cisplatin and
FK228. Cancer Lett. 2016;381(1):124–32. https://doi.org/10.1016/j.canlet.2016.
07.036.
Zaidieh et al. BMC Cancer          (2021) 21:427 Page 17 of 18
31. Itoh T, Terazawa R, Kojima K, Nakane K, Deguchi T, Ando M, et al. Cisplatin
induces production of reactive oxygen species via NADPH oxidase
activation in human prostate cancer cells. Free Radic Res. 2011;45(9):1033–9.
https://doi.org/10.3109/10715762.2011.591391.
32. Marullo R, Werner E, Degtyareva N, Moore B, Altavilla G, Ramalingam SS,
et al. Cisplatin induces a mitochondrial-ROS response that contributes to
cytotoxicity depending on mitochondrial redox status and bioenergetic
functions. PLoS One. 2013;8(11):e81162. https://doi.org/10.1371/journal.pone.
0081162.
33. Sancho P, Galeano E, Nieto E, Delgado MD, García-Pérez AI. Dequalinium
induces cell death in human leukemia cells by early mitochondrial
alterations which enhance ROS production. Leuk Res. 2007;31(7):969–78.
https://doi.org/10.1016/j.leukres.2006.11.018.
34. García-Pérez AI, Galeano E, Nieto E, Sancho P. Dequalinium induces human
leukemia cell death by affecting the redox balance. Leuk Res. 2011;35(10):
1395–401. https://doi.org/10.1016/j.leukres.2011.03.012.
35. Bae Y, Jung MK, Lee S, Song SJ, Mun JY, Green ES, et al. Dequalinium-based
functional nanosomes show increased mitochondria targeting and
anticancer effect. Eur J Pharm Biopharm. 2018;124:104–15. https://doi.org/1
0.1016/j.ejpb.2017.12.013.
36. Murphy MP, Smith RA. Drug delivery to mitochondria: the key to
mitochondrial medicine. Adv Drug Deliv Rev. 2000;41(2):235–50. https://doi.
org/10.1016/S0169-409X(99)00069-1.
37. Zaidieh T, Smith JR, Ball KE, An Q. ROS as a novel indicator to predict
anticancer drug efficacy. BMC Cancer. 2019;19(1):1–14.
38. Lloyd RE, McGeehan JE. Structural analysis of mitochondrial mutations
reveals a role for bigenomic protein interactions in human disease. PLoS
One. 2013;8(7):e69003. https://doi.org/10.1371/journal.pone.0069003.
39. Lloyd RE, Keatley K, Littlewood DT, Meunier B, Holt WV, An Q, et al.
Identification and functional prediction of mitochondrial complex III and IV
mutations associated with glioblastoma. Neuro-Oncology. 2015;17(7):942–
52. https://doi.org/10.1093/neuonc/nov020.
40. McGeehan RE, Cockram LA, Littlewood DTJ, Keatley K, Eccles DM, An Q.
Deep sequencing reveals the mitochondrial DNA variation landscapes of
breast-to-brain metastasis blood samples. Mitochondrial DNA Part A. 2018;
29(5):703–13. https://doi.org/10.1080/24701394.2017.1350950.
41. Guo R, Zong S, Wu M, Gu J, Yang M. Architecture of human mitochondrial
respiratory megacomplex I2III2IV2. Cell. 2017;170(6):1247–57. https://doi.org/1
0.1016/j.cell.2017.07.050.
42. Zong S, Wu M, Gu J, Liu T, Guo R, Yang M. Structure of the intact 14-
subunit human cytochrome c oxidase. Cell Res. 2018;28(10):1026–34. https://
doi.org/10.1038/s41422-018-0071-1.
43. Zhou A, Rohou A, Schep DG, Bason JV, Montgomery MG, Walker JE, et al.
Structure and conformational states of the bovine mitochondrial ATP
synthase by cryo-EM. Elife. 2015;4:e10180. https://doi.org/10.7554/eLife.101
80.
44. Gao X, Wen X, Esser L, Quinn B, Yu L, Yu CA, et al. Structural basis for the
quinone reduction in the bc1 complex: a comparative analysis of crystal
structures of mitochondrial cytochrome bc1 with bound substrate and
inhibitors at the qi site. Biochemistry. 2003;42(30):9067–80. https://doi.org/1
0.1021/bi0341814.
45. Chomyn A, Attardi G. MtDNA mutations in aging and apoptosis. Biochem
Biophys Res Commun. 2003;304(3):519–29. https://doi.org/10.1016/S0006-2
91X(03)00625-9.
46. Hahn A, Zuryn S. Mitochondrial genome (mtDNA) mutations that generate
reactive oxygen species. Antioxidants (Basel). 2019;8(9):392–410.
47. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing.
Nature. 2000;408(6809):239–47. https://doi.org/10.1038/35041687.
48. Lee HC, Yin PH, Lu CY, Chi CW, Wei YH. Increase of mitochondria and
mitochondrial DNA in response to oxidative stress in human cells. Biochem
J. 2000;348(2):425–32. https://doi.org/10.1042/bj3480425.
49. Mizumachi T, Muskhelishvili L, Naito A, Furusawa J, Fan CY, Siegel ER, et al.
Increased distributional variance of mitochondrial DNA content associated
with prostate cancer cells as compared with normal prostate cells. Prostate.
2008;68(4):408–17. https://doi.org/10.1002/pros.20697.
50. Cruz-Bermúdez A, Laza-Briviesca R, Vicente-Blanco RJ, García-Grande A,
Coronado MJ, Laine-Menéndez S, et al. Cisplatin resistance involves a
metabolic reprogramming through ROS and PGC-1α in NSCLC which can
be overcome by OXPHOS inhibition. Free Radic. Biol. Med. 2019;135:167–81.
51. Mohamed Yusoff AA, Zulfakhar FN, Mohd Khair SZN, Wan Abdullah WS,
Abdullah JM, Idris Z. Mitochondrial 10398A>G NADH-dehydrogenase
subunit 3 of complex I is frequently altered in intra-axial brain tumors in
Malaysia. Brain Tumor Res Treat. 2018;6(1):31–8. https://doi.org/10.14791/
btrt.2018.6.e5.
52. Canter JA, Kallianpur AR, Parl FF, Millikan RC. Mitochondrial DNA G10398A
polymorphism and invasive breast cancer in African-American women.
Cancer Res. 2005;65(17):8028–33. https://doi.org/10.1158/0008-5472.CAN-
05-1428.
53. Czarnecka AM, Krawczyk T, Zdrozny M, Lubiński J, Arnold RS, Kukwa W, et al.
Mitochondrial NADH-dehydrogenase subunit 3 (ND3) polymorphism
(A10398G) and sporadic breast cancer in Poland. Breast Cancer Res Treat.
2010;121(2):511–8. https://doi.org/10.1007/s10549-009-0358-5.
54. Li Y, Li X, Wang Z, Feng Z, Li L, Ke X. Subhaplogroup D4b1 enhances the
risk of cervical cancer initiation: a case-control study in southern China. J
Obstet Gynaecol Res. 2016;42(3):325–30. https://doi.org/10.1111/jog.12879.
55. Petros JA, Baumann AK, Ruiz-Pesini E, Amin MB, Sun CQ, Hall J, et al. mtDNA
mutations increase tumorigenicity in prostate cancer. Proc Natl Acad Sci U S
A. 2005;102(3):719–24. https://doi.org/10.1073/pnas.0408894102.
56. Imanishi H, Hattori K, Wada R, Ishikawa K, Fukuda S, Takenaga K, et al.
Mitochondrial DNA mutations regulate metastasis of human breast
cancer cells. PLoS One. 2011;6(8):e23401. https://doi.org/10.1371/journal.
pone.0023401.
57. Yadava N, Schneider SS, Jerry DJ, Kim C. Impaired mitochondrial
metabolism and mammary carcinogenesis. J Mammary Gland Biol
Neoplasia. 2013;18(1):75–87. https://doi.org/10.1007/s10911-012-9271-3.
58. Tanwar M, Dada T, Sihota R, Dada R. Mitochondrial DNA analysis in primary
congenital glaucoma. Mol Vis. 2010;16:518–33.
59. Blein S, Bardel C, Danjean V, McGuffog L, Healey S, Barrowdale D, et al. An
original phylogenetic approach identified mitochondrial haplogroup T1a1
as inversely associated with breast cancer risk in BRCA2 mutation carriers.
Breast Cancer Res. 2015;17(61):1–15.
60. Song Z, Laleve A, Vallières C, McGeehan JE, Lloyd RE, Meunier B. Human
mitochondrial cytochrome b variants studied in yeast: not all are silent
polymorphisms. Hum Mutat. 2016;37(9):933–41. https://doi.org/10.1002/
humu.23024.
61. Shakhssalim N, Houshmand M, Kamalidehghan B, Faraji A, Sarhangnejad R,
Dadgar S, et al. The mitochondrial C16069T polymorphism, not
mitochondrial D310 (D-loop) mononucleotide sequence variations, is
associated with bladder cancer. Cancer Cell Int. 2013;13(1):1–9.
62. Yadav N, Chandra D. Mitochondrial DNA mutations and breast
tumorigenesis. Biochim Biophys Acta. 2013;1836(2):336–44. https://doi.org/1
0.1016/j.bbcan.2013.10.002.
63. Yu M, Zhou Y, Shi Y, Ning L, Yang Y, Wei X, et al. Reduced mitochondrial
DNA copy number is correlated with tumor progression and prognosis in
Chinese breast cancer patients. IUBMB Life. 2007;59(7):450–7. https://doi.
org/10.1080/15216540701509955.
64. Arnould T, Michel S, Renard P. Mitochondria retrograde signaling and the
UPR mt: where are we in mammals? Int J Mol Sci. 2015;16(8):18224–51.
https://doi.org/10.3390/ijms160818224.
65. Cocetta V, Ragazzi E, Montopoli M. Mitochondrial involvement in Cisplatin
resistance. Int J Mol Sci. 2019;20(3384):1–17.
66. Smiraglia DJ, Kulawiec M, Bistulfi GL, Gupta SG, Singh KK. A novel role for
mitochondria in regulating epigenetic modification in the nucleus. Cancer
Biol Ther. 2008;7(8):1182–90. https://doi.org/10.4161/cbt.7.8.6215.
67. Singh KK, Kulawiec M, Still I, Desouki MM, Geradts J, Matsui S. Inter-genomic
cross talk between mitochondria and the nucleus plays an important role in
tumorigenesis. Gene. 2005;354:140–6. https://doi.org/10.1016/j.gene.2005.03.
027.
68. Mok BY, De Moraes MH, Zeng J, Bosch DE, Kotrys AV, Raguram A, et al. A
bacterial cytidine deaminase toxin enables CRISPR-free mitochondrial base
editing. Nature. 2020;583(7817):631–7. https://doi.org/10.1038/s41586-020-24
77-4.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Zaidieh et al. BMC Cancer          (2021) 21:427 Page 18 of 18
